Privia Health Group, Inc. (PRVA)
| Market Cap | 2.91B +2.1% |
| Revenue (ttm) | 2.25B +24.7% |
| Net Income | 21.76M +39.3% |
| EPS | 0.17 +41.3% |
| Shares Out | 126.01M |
| PE Ratio | 136.01 |
| Forward PE | 74.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,080,445 |
| Open | 23.57 |
| Previous Close | 23.99 |
| Day's Range | 22.77 - 23.73 |
| 52-Week Range | 18.77 - 26.51 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 31.08 (+34.78%) |
| Earnings Date | May 7, 2026 |
About PRVA
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with physician practices, health plans, and health systems. It also offers technology and population health tools to enhance providers’ workflows; management services organization that enable providers to focus on their patients by reducing administrative work; and single-TIN medical group that facilitates negotiating power, clinical integration, and alignment of financial incentives. In addition, the company operates acc... [Read more]
Financial Performance
In 2025, Privia Health Group's revenue was $2.12 billion, an increase of 22.26% compared to the previous year's $1.74 billion. Earnings were $22.92 million, an increase of 59.33%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for PRVA stock is "Buy." The 12-month stock price target is $31.08, which is an increase of 34.78% from the latest price.
News
Privia Health price target lowered to $34 from $35 at Canaccord
Canaccord lowered the firm’s price target on Privia Health (PRVA) to $34 from $35 and keeps a Buy rating on the shares. The firm said they posted another solid quarter
Privia Health Group Earnings Call Transcript: Q1 2026
Strong Q1 results featured double-digit growth in providers, attributed lives, and collections, with EBITDA margin expansion and robust cash flow. Guidance for 2026 is reiterated, with attributed lives outlook raised and continued focus on acquisitions and technology innovation.
Privia Health Reports First Quarter 2026 Financial Results
Privia Health Reports First Quarter 2026 Financial Results; Strong First Quarter Performance and Operating Execution; Reiterated Full-Year 2026 Guidance
Privia Health price target lowered to $26 from $30 at Evercore ISI
Evercore ISI lowered the firm’s price target on Privia Health (PRVA) to $26 from $30 and keeps an Outperform rating on the shares. The firm made several price target adjustments
Privia Health to Report First Quarter 2026 Results on Thursday, May 7
ARLINGTON, Va., April 08, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its first quarter ended March 31, 2026 befo...
Privia Health price target raised to $25 from $23 at Barclays
Barclays raised the firm’s price target on Privia Health (PRVA) to $25 from $23 and keeps an Equal Weight rating on the shares. The firm revised models in the healthcare
Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
ARLINGTON, Va., March 24, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that its network of affiliated medical groups, collectively Privia Medical Group, has been named a...
Privia Health price target raised to $35 from $33 at JPMorgan
JPMorgan raised the firm’s price target on Privia Health (PRVA) to $35 from $33 and keeps an Overweight rating on the shares. The firm views the company’s Q4 report as
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia He...
Privia Health price target lowered to $32 from $34 at Citi
Citi analyst Daniel Grosslight lowered the firm’s price target on Privia Health (PRVA) to $32 from $34 and keeps a Buy rating on the shares.
Privia Health price target raised to $33 from $31 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Privia Health (PRVA) to $33 from $31 and keeps a Buy rating on the shares after hosting management talks. The
Privia Health price target raised to $35 from $34 at Canaccord
Canaccord raised the firm’s price target on Privia Health (PRVA) to $35 from $34 and keeps a Buy rating on the shares. The firm said they reported rock solid results
Privia Health price target raised to $32 from $30 at Jefferies
Jefferies analyst Jack Slevin raised the firm’s price target on Privia Health (PRVA) to $32 from $30 and keeps a Buy rating on the shares following an “impressive” Q4 beat.
Privia Health Group Earnings Call Transcript: Q4 2025
Strong 2025 results exceeded guidance, with 16.9% Practice Collections growth and 38.8% higher Adjusted EBITDA. 2026 guidance projects continued double-digit growth, robust cash flow, and disciplined capital deployment, supported by recent acquisitions and technology investments.
Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
All 2025 Operating and Financial Metrics At or Above High End of Guidance Ranges Full-year 2025 Net Income +59.3% from 2024 Full-year 2025 Adjusted EBITDA of $125.5 Million, +38.8% from 2024 Full-year...
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
ARLINGTON, Va., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth-quarter and twelve-month periods ...
Privia Health resumed with an Outperform at RBC Capital
RBC Capital resumed coverage of Privia Health (PRVA) with an Outperform rating and $31 price target Privia is seen as a leading play in physician enablement, a high-growth area at
Privia Health price target raised to $33 from $32 at JPMorgan
JPMorgan analyst Lisa Gill raised the firm’s price target on Privia Health (PRVA) to $33 from $32 and keeps an Overweight rating on the shares. The firm updated the company’s
Privia Health initiated with an Outperform at BMO Capital
BMO Capital analyst Sean Dodge initiated coverage of Privia Health (PRVA) with an Outperform rating and $30 price target The firm sees Privia as a “stable long-term earnings compounder with
Privia Health price target raised to $34 from $32 at Canaccord
Canaccord raised the firm’s price target on Privia Health (PRVA) to $34 from $32 and keeps a Buy rating on the shares. The firm said its thesis on the copany
Privia Health price target raised to $23 from $22 at Barclays
Barclays analyst Andrew Mok raised the firm’s price target on Privia Health (PRVA) to $23 from $22 and keeps an Equal Weight rating on the shares post the Q3 report.
Privia Health price target raised to $30 from $28 at Evercore ISI
Evercore ISI raised the firm’s price target on Privia Health (PRVA) to $30 from $28 and keeps an Outperform rating on the shares. The company’s execution track record merits a
Privia Health price target raised to $31 from $30 at Citizens JMP
Citizens JMP raised the firm’s price target on Privia Health (PRVA) to $31 from $30 and keeps an Outperform rating on the shares. Privia Health fired on all cylinders in
Privia Health Group Earnings Call Transcript: Q3 2025
Q3 2025 saw robust growth in practice collections, adjusted EBITDA, and attributed lives, driven by strong value-based care performance and new provider additions. The company raised its 2025 outlook and is expanding through a major ACO acquisition, maintaining strong cash flow and financial flexibility.
Privia Health Reports Third Quarter 2025 Financial Results
Privia Health Reports Very Strong Q3 and YTD Results Across the Business; FY'25 Guidance Raised Above High End for All Key Operating and Financial Metrics